J W Egan - JoVE Visualize

Showing results (1-10 of 22) with videos related to

Pageof 3

Sort By:

The Journal of Pharmacology and Experimental Therapeutics|June 1, 1987

Comparison of the effects of a thromboxane synthase inhibitor or prostacyclin in combination with a phosphodiesterase inhibitor for prevention of experimental thrombosis and sudden death in rabbitsE F Smith, J W Egan

Prostaglandins, Leukotrienes, and Essential Fatty Acids|October 1, 1989

BM 13.505, a selective thromboxane receptor antagonist, reduces myocardial infarct size following coronary artery reperfusionE F Smith, C Q Earl, J W Egan

Pharmacology|January 1, 1989

Effect of propranolol on ischemic myocardial damage and left ventricular hypertrophy following permanent coronary artery occlusion or occlusion followed by reperfusionE F Smith, J W Egan, D E Griswold

Pharmacology|January 1, 1991

Identification of cardiac endothelin binding sites in rats: downregulation of left atrial endothelin binding sites in response to myocardial infarctionP Nambi, M Pullen, J W Egan, et al.

The Veterinary Record|August 30, 1997

Performance of the single intradermal comparative tuberculin test in identifying cattle with tuberculous lesions in Irish herdsE Costello, J W Egan, F C Quigley, et al.

Biochemistry and Cell Biology = Biochimie Et Biologie Cellulaire|June 1, 1988

DNA-mediated transfection as a model for oncogenesisM P Moyer, J W Egan, J B Aust, et al.

Circulatory Shock|October 1, 1989

Effect of a selective V1 vasopressin receptor antagonist on the sequelae of endotoxemia in the conscious ratJ W Egan, M Jugus, L B Kinter, et al.

Journal of Cardiovascular Pharmacology|May 1, 1989

Reduction of myocardial damage and polymorphonuclear leukocyte accumulation following coronary artery occlusion and reperfusion by the thromboxane receptor antagonist BM 13.505E F Smith, D E Griswold, J W Egan, et al.

Clinical Therapeutics|February 24, 2001

Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study GroupD Einhorn, M Rendell, J Rosenzweig, et al.

Diabetes Care|November 25, 2000

Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study GroupS Aronoff, S Rosenblatt, S Braithwaite, et al.

Pageof 3

Showing results (1-10 of 22) with videos related to

Sort By:

Pageof 3

The Journal of Pharmacology and Experimental Therapeutics|June 1, 1987

Comparison of the effects of a thromboxane synthase inhibitor or prostacyclin in combination with a phosphodiesterase inhibitor for prevention of experimental thrombosis and sudden death in rabbitsE F Smith, J W Egan

Prostaglandins, Leukotrienes, and Essential Fatty Acids|October 1, 1989

BM 13.505, a selective thromboxane receptor antagonist, reduces myocardial infarct size following coronary artery reperfusionE F Smith, C Q Earl, J W Egan

Pharmacology|January 1, 1989

Effect of propranolol on ischemic myocardial damage and left ventricular hypertrophy following permanent coronary artery occlusion or occlusion followed by reperfusionE F Smith, J W Egan, D E Griswold

Pharmacology|January 1, 1991

Identification of cardiac endothelin binding sites in rats: downregulation of left atrial endothelin binding sites in response to myocardial infarctionP Nambi, M Pullen, J W Egan, et al.

The Veterinary Record|August 30, 1997

Performance of the single intradermal comparative tuberculin test in identifying cattle with tuberculous lesions in Irish herdsE Costello, J W Egan, F C Quigley, et al.

Biochemistry and Cell Biology = Biochimie Et Biologie Cellulaire|June 1, 1988

DNA-mediated transfection as a model for oncogenesisM P Moyer, J W Egan, J B Aust, et al.

Circulatory Shock|October 1, 1989

Effect of a selective V1 vasopressin receptor antagonist on the sequelae of endotoxemia in the conscious ratJ W Egan, M Jugus, L B Kinter, et al.

Journal of Cardiovascular Pharmacology|May 1, 1989

Reduction of myocardial damage and polymorphonuclear leukocyte accumulation following coronary artery occlusion and reperfusion by the thromboxane receptor antagonist BM 13.505E F Smith, D E Griswold, J W Egan, et al.

Clinical Therapeutics|February 24, 2001

Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study GroupD Einhorn, M Rendell, J Rosenzweig, et al.

Diabetes Care|November 25, 2000

Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study GroupS Aronoff, S Rosenblatt, S Braithwaite, et al.

Pageof 3